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The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well
characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis
and bone resorption. However, this system has also been shown to influence biologic
processes beyond the skeletal system, including in the immune system and in cancer.
RANKL/RANK signaling is important in lymph-node development, lymphocyte differentia-
tion, dendritic cell survival,T-cell activation, and tolerance induction.The RANKL/RANK axis
may also have direct, osteoclast-independent effects on tumor cells. Indeed, activity of
the RANKL/RANK pathway in cancer cells has been correlated with tumor progression and
advanced disease. Denosumab, a fully human monoclonal antibody against RANKL, inhibits
osteoclastogenesis and is widely used not just for the treatment of osteoporosis, but for
the prevention of skeletal-related events from bone metastases in solid malignancies such
as breast and prostate cancer. The potential effects of denosumab on the immune sys-
tem have been largely ignored. Nevertheless, with the emergence of immunotherapies for
cancer, denosumab may impact the effectiveness of these therapies, especially if they are
given in combination. In this article, we review the role of RANKL/RANK in bone, immunity,
and cancer. Examining the potential effects of routine treatment with denosumab beyond
the bone represents an important area of investigation.
Keywords: receptor activator of nuclear factor-kappa B, RANK ligand, dendritic cells, T-cell activation, immune
tolerance, denosumab, prostate cancer, cancer immunology
INTRODUCTION
The skeletal architecture is maintained through a complex remod-
eling process mediated by osteoblasts, responsible for bone forma-
tion, and osteoclasts, responsible for bone resorption. Osteoblasts
are derived from mesenchymal stem cells, and their differentia-
tion is induced by several specific transcription factors, including
core-binding factor α1 (Cbfa1) and osterix (Osx), as well as by the
bone morphogenic proteins BMP-2, BMP-4, and BMP-7. Mature
osteoblasts synthesize and secrete type I collagen, the major struc-
tural protein in bone matrix. Osteoblasts also secrete non-collagen
proteins including osteocalcin, osteopontin, and bone sialopro-
tein, as well as cytokines including IGF-1, IL-1, and IL-6 (1).
In contrast, osteoclasts are hematopoietic in origin and derive
from granulocyte-macrophage progenitor cells. Osteoclastogene-
sis requires stimulation by macrophage-colony stimulating factor
(M-CSF) and the binding of receptor activator of nuclear factor-
κB ligand (RANKL), expressed on osteoblasts, to RANK receptor
on the osteoclast precursors. RANKL is a member of the tumor
necrosis factor (TNF) family, as is also known as TNF-related
activation-induced cytokine (TRANCE), osteoprotegerin ligand
(OPGL), and osteoclast differentiation factor (ODF). Osteoclasts
secrete proteases and hydrogen ions that dissolve and digest bone
matrix, causing bone resorption. Osteoclast formation and func-
tion is stimulated by RANKL/RANK interaction, as well as by IL-1,
IL-6, IL-11, transforming growth factor alpha (TGFα), TNFα, and
TNFβ (2, 3). Osteoclasts are inhibited by multiple soluble factors,
including OPG, an endogenous decoy receptor of RANKL secreted
by osteoblasts and expressed in several other tissues, including
lung, heart, and kidney. (4).
Tumor-derived factors including parathyroid hormone-
releasing protein (PTHrP), prostaglandin E2 (PGE2), TNFα, and
interleukins, have been demonstrated to enhance RANKL expres-
sion by osteoblasts and other bone stromal cells present, and
diminish OPG expression (5). Some tumors, including prostate
cancer, breast cancer, renal carcinoma, and multiple myeloma,
produce RANKL which may directly contribute to osteoclasto-
genesis (6).
IMMUNITY AND THE RANKL/RANK SYSTEM
Recent work has demonstrated that the RANKL/RANK sys-
tem also serves an important role in the immune system,
including in lymph-node development, lymphocyte differenti-
ation, dendritic cell survival and T-cell activation, and toler-
ance induction. RANKL is essential in lymph-node organo-
genesis, as mice lacking this molecule develop without lymph
nodes, but retain normal splenic architecture and Peyer’s patches
(PP). Additionally, this work suggested that RANKL is impor-
tant for the regulation of early T- and B-lymphocyte develop-
ment, especially for CD25+CD44− thymocyte progression to
CD25−CD44−, and for B220+CD43+CD25− pro-B-cell pro-
gression to B220+CD43−CD25+ pre-B cells (7). Furthermore,
RANKL/RANK, along with CD40L/CD40, signaling is required
for the development of medullary thymic epithelial cells (mTECs),
which express the autoimmune regulator (AIRE) gene and mediate
T-cell self-tolerance (8, 9).
Receptor activator of nuclear factor-κB ligand is primarily
expressed on activated CD4+ and CD8+ T cells. RANKL is
upregulated with T-cell receptor (TCR) stimulation, and may
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FIGURE 1 | RANKL/RANK signaling in osteoclast formation and DC
activation. (A). RANKL/RANK interactions enhances osteoclast
differentiation and bone resorption. (B) RANKL/RANK interactions also occur
in the immune system, driving dendritic cell survival, and activation.
(C) Signaling occurs via the recruitment of adaptor molecules, most
importantly TNF receptor-associated factor 6 (TRAF6), which activates
downstream signaling pathways, including that of nuclear factor-κB (NFκB) as
well as mitogen-associated protein kinases (MAPK) such as p38, c-Jun
N-terminal protein kinases (JNK), and the extracellular signal-regulated
kinases (ERK). TRAF6 also complexes with c-Src to activate the antiapoptotic
serine/threonine kinase AKT/PKB. (D) Immature interstitial DCs co-express
both RANKL and RANK, and demonstrate autocrine stimulation. However, as
these cells mature, they down-regulate RANKL and become dependent on
exogenous factors.
have direct effects on T cells via Jun N-terminal protein kinases
(JNK) activation, including enhancing the cell’s own prolifera-
tion and function (10). RANKL interfaces with RANK, which
is highly expressed on dendritic cells (DCs) (11). This inter-
action increases DC survival and enhances induction of T-cell
responses. RANKL/RANK signaling (Figure 1) is mediated by
the recruitment of adaptor molecules, most importantly TNF
receptor-associated factor 6 (TRAF6) (12), which activates down-
stream signaling pathways, including that of nuclear factor-κB
(NFκB) as well as mitogen-associated protein kinases (MAPK)
such as p38, c-JNK, and the extracellular signal-regulated kinases
(ERK) (13). TRAF6 complexes with c-Src to activate the antiapop-
totic serine/threonine kinase AKT/PKB (14). RANK triggering
also can enhance DC survival via induction of the antiapoptotic
protein B-cell lymphoma-extra large (Bcl-xl) (15), which has been
demonstrated to be critical to DC survival in vivo (16).
Receptor activator of nuclear factor-κB ligand induces DC
expression of multiple activating cytokines, including IL-1, IL-6,
IL-12, and IL-15 (17). Mature DCs pulsed with soluble RANK-
L prior to immunization exhibited enhanced abundance and
longevity in draining lymph nodes in vivo, as well as improved
CD4+ T-cell priming to purified protein derivative (PPD) and
ovalbumin (OVA) antigen (18). DCs transfected with recombinant
adenovirus vectors demonstrated improved survival and mainte-
nance of CD83 and CD86 surface markers with the addition of
RANKL (19). OPG deficient mice demonstrate a twofold to five-
fold greater capacity to stimulate T-cell proliferation, despite sim-
ilar MHCII and CD86 levels, suggesting that the OPG’s function
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as a molecular brake on the RANKL/RANK system also occurs
in the immune system (20). Transduction of DCs with RANKL-
RANK, but not CD40L/CD40, pairs enhanced the expression
of costimulatory signals and augmented corresponding effector
and memory cytotoxic T-lymphocyte (CTL) responses toward a
tumor-associated antigen (TAA) (21).
The CD40L/CD40 system has functional similarities to
RANKL/RANK, and also enhances DC survival and antigen-
specific T-cell responses. However, CD40L is only expressed on
activated CD4+ cells, may act at an earlier phase during the
immune response than RANKL (22). CD40L also influences T-
cell dependent B-cell responses whereas RANKL does not (23,
24). RANKL/RANK has been demonstrated to enable CD4+
T-cell priming independent of CD40L/CD40. The two systems
may cooperate, and the predominant pathway employed may be
influenced by particular antigens. RANKL inhibition in wild-
type mice resulted in modestly reduced CD4+ T-cell response
to lymphocytic choriomeningitis virus (LCMV), and inhibition in
CD40L-deficient mice resulted in the near absence of CD4+T-cell
proliferative response and IFN-gamma expression (25).
Autocrine RANKL/RANK signaling has also been demon-
strated in the immune system. Immature interstitial DCs found
in the dermis and liver co-express both RANKL and RANK, and
demonstrate longevity most likely mediated in an autocrine fash-
ion. However, as these cells mature, they down-regulate RANKL
and become dependent on exogenous factors for activation and
survival (26). RANKL has additionally been recently described
to similarly upregulate monocyte/macrophage survival, effector
function, and antigen presentation. This study also demonstrated
that blockade of RANKL reduced death from lipopolysaccharide
(LPS)-induced endotoxic shock in a murine model (27)
Receptor activator of nuclear factor-κB ligand/RANK signal-
ing may also serve important inhibitory functions in the immune
system. The RANKL/RANK system has been implicated in the
induction of tolerance and may also modulate immunosuppres-
sion. RANKL treatment enhanced tolerance to oral OVA adminis-
tration, and increased IL-10 mRNA expression in PP DCs, suggest-
ing important differences between mucosal and peripheral DCs
(28). RANKL-RANK signaling has been shown to be critical to
CD4+CD25+ regulatory T cells (Treg) generation, but not effec-
tor function, in pancreatic lymph nodes. Blockade of the pathway
in a CD8+ T-cell mediated model of type I diabetes, resulted
in diminished Treg accumulation and rapid destruction of beta
islet cells (29). RANKL expressed on keratinocytes in ultraviolet-
inflamed skin interacts with epidermal DCs to increase the genera-
tion of local and systemic CD4+CD25+ Tregs (30). Interestingly,
T-cells have also been shown to upregulate RANKL in response
to tolerogenic signal, in the absence of RANK expression on DCs
(31), and RANKL expression is also increased in CD8+ T cells
undergoing deletion (32).
Negative regulation of RANKL/RANK by OPG also occurs in
the immune system, and OPG appears to have direct DC effects.
DCs in OPG knockout (KO) mice demonstrate prolonged sur-
vival as well as enhanced proinflammatory cytokine response to
Escherichia coli LPS stimulation. Replacement of OPG to OPG
KO cultures diminished survival and cytokine expression to wild-
type levels (33). However, treatment with OPG has also been
demonstrated not to affect cellular immunity with regard to con-
tact hypersensitivity or Mycobacterium infection. This study also
showed that OPG induced modest co-stimulation of T cells, as
well as increased humoral responses, though the mechanism of
this is unclear (34). OPG also acts as a decoy receptor for TNF-
related apoptosis-inducing ligand (TRAIL) and inhibits TRAIL-
mediated apoptosis. Interestingly, TRAIL in turn may inhibit the
bone-protective function of OPG (35).
The clinical importance of immune changes driven by
RANKL/RANK signaling is uncertain. RANKL and RANK KO
mice do not demonstrate diminished DC or monocyte develop-
ment, and the function of these cells remains intact, suggesting that
the interaction may not be required for activation (7, 36). A study
evaluating six individuals with autosomal recessive osteopetrosis
secondary to mutations in TNFSF11, the gene encoding RANKL,
did not identify significant differences from controls in the num-
ber of B and T-cell subsets, T-cell proliferation, or propensity to
apoptosis. Lower levels of Th1 and Th2 cytokine expression fol-
lowing stimulation was seen in one individual. It is possible that
these mutant RANKL proteins may retain immune, but not bone,
functions (37).
CANCER AND THE RANKL/RANK SYSTEM
The RANKL/RANK system mediates important osteoclast-
dependent pathologic processes in metastatic disease to bone. The
“vicious cycle” of reciprocal feedback between tumor proliferation
and bone breakdown is well described. The invasion of metasta-
tic cells and the production of tumor-associated factors enhances
bone resorption, which in turn causes the release of immobilized
growth factors that further promote tumor proliferation. Multiple
studies demonstrate diminished growth and increased apoptosis
in skeletal tumor burden secondary to osteoclast inhibition with
RANKL blockade. This concept has been shown in murine mod-
els of prostate cancer (38, 39), breast cancer (40), and multiple
myeloma (41). However, studies indicate that the RANKL/RANK
system may also have complex osteoclast-independent effects on
malignancies. RANK-expressing tumors include prostate can-
cer, breast cancer, lung cancer, renal carcinoma, and melanoma.
Importantly, a series evaluating multiple solid tumors did not
demonstrate significant differences in RANK expression between
primary tumors and corresponding bone metastases (42).
Increased expression of RANKL, RANK, and OPG is found
in prostate carcinoma tissue whereas expression is low in nor-
mal cells. Furthermore, expression of all three proteins was pos-
itively correlated with clinicopathologic parameters indicating
more aggressive and advanced disease, including Gleason score,
PSA level, androgen receptor (AR) negativity, and presence of
metastases (43). Additionally, RANKL has been shown in prostate
cancer to activate IκB kinase α (IKKα), and inhibit expression
of the metastasis suppressor Maspin, leading to progressive dis-
ease. Active IKKα was positively correlated with tumor infiltration
of RANKL-expressing lymphocytes (44). RANKL expression has
also been associated with epithelial-to-mesenchymal transition
(EMT), a morphologic switch in which cancer cells upregu-
late mesenchymal-associated genes and assume an increasingly
migratory and invasive phenotype with loss of cell-cell adhe-
sion. Increased RANKL expression has been described in human
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prostate cancer EMT models, suggesting the protein may represent
a novel marker of this transition (45).
The RANKL/RANK system is necessary for the development
of lobulo-alveolar mammary structures and RANKL and RANK
KO mice demonstrate an inability to lactate, as well as impaired
proliferation of alveolar epithelium (46). In a mouse model of
mammary tumorigenesis, gain-of-function in RANK signaling
resulted in increased formation of pre-neoplasias and tumors,
while inhibition of RANKL diminished tumorigenesis (47). Addi-
tionally, RANKL is induced by the progestin medroxyprogesterone
acetate (MPA), and the axis has been implicated in the pathogen-
esis of progestin-mediated breast cancer. Inactivation of RANK
or deletion of RANK resulted in diminished and delayed MPA-
driven breast cancer. RANKL treatment decreased cell death in
response to doxorubicin and irradiation (48). Tumor-infiltrating
CD4+CD25+FoxP3+ Treg cells have been associated with more
aggressive breast cancer phenotypes, and these cells have eluci-
dated to be a major source of RANKL production. Pulmonary
metastasis in a model of breast cancer driven by overexpres-
sion of the ErbB2 (c-Neu) proto-oncogene, was shown to be
mediated by RANKL signaling both from Treg expression and
exogenous administration (49). RANK overexpression has been
demonstrated to directly induce EMT as well as stem-like pheno-
types in both normal mammary epithelial cells and tumor cells.
RANK mRNA is more highly expressed in ER and PR negative
tumors, which generally have poorer prognosis, and is correlated
with high pathologic grade and metastasis (50, 51).
The RANKL/RANK system has also been investigated in renal
cell carcinoma (RCC), and may have different roles among the
several histologic subtypes. Analysis of RCC tissues demonstrated
that RANKL mRNA was significantly higher in clear cell RCCs
as compared to papillary RCCs, chromophobe RCCs, or non-
neoplastic tissues. RANK mRNA expression was increased and
OPG expression was decreased in clear cell RCCs as compared
to non-neoplastic tissue. The RANKL to OPG mRNA ratio was
higher in clear cell RCCs than papillary RCCs and non-neoplastic
tissue. Additionally, immunostaining for RANKL protein expres-
sion was significantly greater in clear cell RCCs than the other
histologies. In a clear cell RCC cell line, Caki-1, RANKL trans-
fection accelerated tumor migration fourfold and led to greater
dispersion and involvement of tumor margins histologically as
compared to control. OPG administration blocked this effect in
a dose-dependent manner. Clinically, patients with RANKL- and
RANK-high tumors were seen to have shorter disease-free survival,
disease-specific survival, bone-metastasis-free survival. OPG-high
tumors were correlated with longer disease-free survival, and no
OPG-high tumor developed bone metastasis (52).
Receptor activator of nuclear factor-κB ligand-triggered tumor
migration was demonstrated in a lung cancer model via upregula-
tion of intercellular adhesion molecule-1 (ICAM-1) (53). Regres-
sion of metastatic lung adenocarcinoma driven by an anaplastic
lymphoma kinase (ALK) translocation with denosumab treat-
ment by has been described in a case report. Down-regulation
of AKT/PKB, which is downstream of the ALK fusion product,
secondary to the lack of PI3K activation in RANK inhibition
has been postulated as a possible mechanism of this observa-
tion (54). RANKL expression has been found in a proportion
of HCV- and HBV-driven hepatocellular carcinoma (HCC), and
significantly correlated to the development of bone metastases
(55). RANKL-expression is also found in multiple myeloma and
chronic lymphocytic leukemia, and induces cytokines involved
in disease pathogenesis, including TNF, IL-6, and IL-8. A novel
Fc-engineered RANK-Fc fusion protein, but not denosumab, was
shown to induce NK cell-mediated antitumor immunity against
RANKL-expressing targets (56). RANKL, RANK, and OPG were
variably expressed in tumors of the thyroid, including papillary
carcinomas, medullary carcinomas, and macrovesicular adenomas
(57).
The RANKL/RANK pathway is may exert important effects
on the behavior of cancer cells within the bone microenviron-
ment. RANKL expressed by osteoblasts and stromal cells in bone
tissue may represent an important chemoattractant or “soil” fac-
tor that underlies preferential metastasis of certain tumors to the
bone. RANKL stimulation of prostate cancer cells can induce
multiple signaling pathways which stimulate cellular migration,
chemotaxis, and invasion through collagen matrix (58). RANKL,
RANK, and OPG expression was greater in bone metastases
than lymph-node metastases in prostate cancer (43). Similarly,
RANK-expressing breast and prostate cancer cell lines demon-
strate upregulation of matrix metalloproteinase-1 (MMP-1) and
subsequent migration and invasion upon RANKL administration
(59). High RANK and low OPG expression in primary breast
cancer tumors correlated with accelerated bone metastasis and
shortened skeletal-disease-free survival (60). In vivo RANKL inhi-
bition in malignant melanoma reduced metastasis to bone, but
not other sites, and diminished morbidity. These findings were
independent of osteoclast-mediated effects (61).
The role of OPG may be an important factor in several malig-
nancies. OPG has been demonstrated to inhibit apoptosis in a
range of tumor cells, likely through its action as the decoy receptor
for TRAIL. OPG has been demonstrated to be a survival factor in
prostate cancer (62) and well as breast cancer (63), and multiple
myeloma (64). Increased serum OPG has also been correlated with
poor prognosis in gastric carcinoma (65) and bladder carcinoma
(66).
CLINICAL TRIAL EXPERIENCE WITH DENOSUMAB
Denosumab is a fully human monoclonal antibody that avidly
binds RANKL and blocks RANKL/RANK interaction and sig-
naling. Unlike OPG, denosumab does not bind to TRAIL (67).
Denosumab is FDA-approved for the prevention of skeletal-related
events (SREs) from bone metastases in solid malignancies other
than multiple myeloma (68), as well as for the treatment of
osteoporosis in postmenopausal women and men at high risk
for fracture (69). The agent, administered subcutaneously, is
dosed at 120 mg every 4 weeks for the prevention of SREs, and
dosed at 60 mg every 6 months for its osteoporosis and bone loss
indications. The mean half-life of denosumab is 28 days.
A meta-analysis, including three phase III studies, evaluating
denosumab in comparison to zoledronic acid for the reduction
of SREs demonstrated significantly decreased incidence of SREs
(risk ratio (RR) 0.84, 95% confidence interval (CI) 0.80–0.88),
as well as delayed onset of first SRE (RR 0.83, 95% CI 0.75–
0.90) and time to worsening of pain (RR 0.84, 95% CI 0.77–0.91).
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Denosumab, which is not renally excreted, had a lower incidence
of renal toxicity, but had an increased risk of hypocalcemia. No
differences were seen in the incidence of new cancers, infections,
or osteonecrosis of the jaw (ONJ) (70). A recent phase III trial
also demonstrated that monthly denosumab in non-metastatic
castration-resistant prostate cancer significantly increased bone-
metastasis-free survival and delayed time to first bone metastasis
compared to placebo, suggesting another potential role for the
therapy. No difference in infections was seen, however denosumab
was associated with increased incidence of ONJ and hypocal-
cemia (71). A phase III study investigating adjuvant denosumab
for the prevention of bone metastasis in early-stage breast cancer
is ongoing (D-CARE, NCT01077154).
The FREEDOM trial evaluated twice yearly denosumab for the
prevention of fractures in postmenopausal women with osteo-
porosis. The phase III trial demonstrated decreased incidence of
vertebral fracture (RR 0.32, 95% CI 0.26–0.41), hip fracture [haz-
ard ratio (HR) 0.60, 95% CI 0.37–0.97], and non-vertebral fracture
(HR 0.80, 95% CI 0.67–0.95) as compared with placebo. The
incidence of cancer or infection was not increased in the treat-
ment group, and there were no reported cases of hypocalcemia
or ONJ with denosumab (72). Results from the first 2 years of
the FREEDOM extension did not demonstrate a trend toward
increased incidence of malignancy or infection over time. ONJ
was reported in two patients in the cross-over denosumab group
of the extension trial (73). Denosumab was also studied for the
prevention of osteoporosis in men with non-metastatic prostate
cancer receiving androgen-deprivation therapy, which is associ-
ated with bone loss and fractures. A phase III study demonstrated
significantly increased bone mineral density at all measured sites
and decreased incidence of new vertebral fractures with treat-
ment. Adverse events were comparable between the denosumab
and placebo groups. Infection-related serious adverse events were
seen in 4.6% of patients receiving placebo, and 5.9% of patients
receiving denosumab. No change in PSA levels over time were
detected, and there were no cases of ONJ (74).
CONCLUSION
The role of RANKL/RANK in immunity is complex, and evidence
suggests that this system has multiple divergent effects, both in the
generation of active immune responses, as well as in the induc-
tion of tolerance (Table 1). RANKL/RANK may have differential
roles among particular populations of DCs and other immune
cells. This system has been also been shown to influence disease
processes outside of the skeletal system, including in cancer. While
the osteoclast-dependent effects of RANKL/RANK signaling in
bone metastases are well described, recent data has shown that
RANKL/RANK signaling may have osteoclast-independent, direct
tumor effects. The system has been studied in a range of malig-
nancies, and RANKL/RANK activity has largely demonstrated a
positive correlation with tumor progression and advanced disease.
Denosumab is routinely employed in clinical practice for the
prevention of SREs in cancer and fractures in osteoporosis. No
change in the rates of infection or new cancers was seen in clinical
trials with denosumab, and long-term surveillance is ongoing (75).
Treatment is associated with a significant risk of ONJ, the etiology
of which is unclear (76). Treatment-induced effects on immunity
Table 1 | Divergent effects of RANKL/RANK signaling on the immune
system.
Enhancement of immunity Inhibition of immunity
Regulation of T- and B-lymphocyte
development
Development of medullary thymic
epithelial cells (mTECs), which
mediate T-cell self-tolerance
Lymph-node organogenesis Enhanced tolerance in Peyer’s Patch
DCs
Increased DC survival, cytokine
expression, and migration
Generation of regulatory T cells
(Tregs)
Enhanced induction of T-cell
responses
Induction of T-cell tolerance and
deletion
and/or inflammation could play a role in this disease. This treat-
ment related side effect is also seen with bisphosphonates, which
are also known to have significant immunomodulatory effects
beyond their effects on bone (77, 78). Otherwise, little clinical evi-
dence exists to support significant global immune dysregulation
due to RANKL inhibition. Also, there is evidence that suggests the
presence of redundant pathways may limit consequential immune
effects of denosumab administration (79). The present experi-
mental evidence primarily suggests that RANKL/RANK signaling
potentially mediates negative outcomes in cancer. While there is
some evidence to suggest that OPG promotes tumor antiapopto-
sis, this is likely mediated by its inhibition of TRAIL, which is not
a property shared by denosumab.
However, our understanding of the role of the RANKL/RANK
pathway in cancer remains limited, and represents an important
area of investigation. While denosumab may induce divergent
effects of the immune system, these may occur at different times.
For example, with initiation of denosumab, a reduction of mTECs
or Tregs might transiently enhance anti-tumor immunity. These
changes might be counterbalanced by the effects of denosumab
on dendritic cell activation and tolerance over time, especially in
cancer patients, who receive the agent at a higher dose and fre-
quency. Further investigation may be helpful to assess whether
the axis has positive or negative effects on anti-tumor immunity,
especially in prostate cancer and melanoma, where FDA-approved
immunotherapies are available. Immune-based therapies serve an
increasingly important role in the management of solid malignan-
cies, and include sipuleucel-T, an autologous dendritic cell vaccine
against the prostatic acid phosphatase (PAP) antigen, as well as
ipilimumab, a monoclonal antibody against CTL associated anti-
gen 4 (CTLA-4). Patients may be inadvertently combining these
treatments, the effect of which is unclear. Sequencing of deno-
sumab with these immunotherapies could also potentially affect
their immunogenicity. The RANKL/RANK axis may also be mod-
ified by other co-administered medications, and this represents
an important area of investigation (80). Additionally, monitor-
ing of the RANKL/RANK axis may potentially serve an important
prognostic or diagnostic role in certain cancers.
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